Inotek Pharmaceuticals Corporation (ITEK) Receives Analyst Rating

Inotek Pharmaceuticals Corporation (ITEK) : 2 brokerage houses believe that Inotek Pharmaceuticals Corporation (ITEK) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 2 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Inotek Pharmaceuticals Corporation (ITEK) : 2 investment research analysts covering Inotek Pharmaceuticals Corporation (ITEK) have an average price target of $32 for the near short term. The highest target price given by the Brokerage Firm to the stock is $40 and the lowest target is $24 for the short term. Analysts expect the variance to be within $11.31 of the average price.


Inotek Pharmaceuticals Corporation (NASDAQ:ITEK): The stock opened in the green at $8.05 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $8.15 and a low of $7.67 for the day. The stock did not find buyers even at the lows and closed at $7.99 recording a loss of -0.37%. 752,251 shares exchanged hands during the trading day. The stock had closed at $8.02 in the previous days trading.

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company advancing molecules with new mechanisms of action to address diseases of the eye. The Companys business strategy is to develop and progress its product candidates through human clinical trials. The Company is focused on the discovery, development and commercialization of therapies for glaucoma. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that is designed to lower intraocular pressure (IOP) by restoring the eyes natural pressure control mechanism. The Companys product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed dose combination (FDC) of trabodenoson with latanoprost given once-daily (QD).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.